Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1771 AL 1785

Identification of a small molecule that selectively activates alpha-synuclein translational expression

Ross NT, Metkar SR, Le H, Burbank J, Cahill C, Germain A, MacPherson L, Bittker J, Palmer M, Rogers J, Schreiber SL.

2011 Feb 4 [updated 2011 Feb 15]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–.

[Development of gene therapy in major brain diseases]

Fan L, Jiang XG.

Yao Xue Xue Bao. 2010 Sep;45(9):1095-102.

Parkinson’s disease DBS: what, when, who and why? The time has come to tailor DBS targets

Okun MS, Foote KD.

Expert Rev Neurother. 2010 Dec;10(12):1847-57. doi: 10.1586/ern.10.156.

Clozapine withdrawal catatonia or lethal catatonia in a schizoaffective patient with a family history of Parkinson's disease

Thanasan S, Jambunathan ST.

Afr J Psychiatry (Johannesbg). 2010 Nov;13(5):402, 404.

[Autophagy-lysosome pathway and Parkinson's disease]

Fan XN, Wang G, Chen SD.

Sheng Li Ke Xue Jin Zhan. 2010 Aug;41(4):272-4.

Capturing side-effect of medication to identify persons at risk of delirium

Lauretani F, Ceda GP, Maggio M, Nardelli A, Saccavini M, Ferrucci L.

Aging Clin Exp Res. 2010 Oct-Dec;22(5-6):456-8. doi: 10.1007/BF03324944.

[Discovery of an antiparkinsonian drug: zonisamide]

Murata M.

Rinsho Shinkeigaku. 2010 Nov;50(11):780-2. doi: 10.5692/clinicalneurol.50.780.

[Transcranial magnetic stimulation (TMS) in clinical neurology]

Matsumoto H, Ugawa Y.

Rinsho Shinkeigaku. 2010 Nov;50(11):803-7. doi: 10.5692/clinicalneurol.50.803.

[Genetic basis of sponadic Parkinson disease: common disease-multiple rare variants]

Mitsui J.

Rinsho Shinkeigaku. 2010 Nov;50(11):865-6. doi: 10.5692/clinicalneurol.50.865.

[Clinicopathological features of sporadic frontotemporal lobar degeneration with TDP-43-positive inclusions]

Yokota O.

Rinsho Shinkeigaku. 2010 Nov;50(11):1018-21. doi: 10.5692/clinicalneurol.50.1018.

[Stimulation therapies for Parkinson's disease: over the past two decades]

Benabid AL.

Bull Acad Natl Med. 2010 Oct;194(7):1273-86.

[Update on the pathophysiology of Parkinson' disease]

Duyckaerts C, Sazdovitch V, Seilhean D.

Bull Acad Natl Med. 2010 Oct;194(7):1287-303; discussion 1303-4.

[Psychological and behavioural disorders in Parkinson's disease]

Fénelon G, Césaro P.

Bull Acad Natl Med. 2010 Oct;194(7):1305-18; discussion 1318-9.

[Pathophysiology of Parkinson's disease: an update]

Tremblay L.

Bull Acad Natl Med. 2010 Oct;194(7):1321-31; discussion 1331-2.

The cyanobacteria derived toxin Beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis

Banack SA, Caller TA, Stommel EW.

Toxins (Basel). 2010 Dec;2(12):2837-50. doi: 10.3390/toxins2122837. Epub 2010 Dec 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias